14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 8th May 2024 CTMX stock ended at $4.19. This is 2.95% more than the trading day before Tuesday, 7th May 2024. During the day the stock fluctuated 10.95% from a day low at $3.79 to a day high of $4.21.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Oct 19, 2016 $12.98 $12.98 $12.61 $12.76 42 300
Oct 18, 2016 $13.05 $13.27 $12.93 $12.97 51 900
Oct 17, 2016 $12.71 $13.17 $12.59 $12.97 78 600
Oct 14, 2016 $13.06 $13.20 $12.06 $12.78 143 400
Oct 13, 2016 $13.10 $13.46 $12.76 $12.95 109 000
Oct 12, 2016 $14.21 $14.39 $13.02 $13.18 102 900
Oct 11, 2016 $15.01 $15.08 $14.16 $14.44 69 600
Oct 10, 2016 $15.11 $15.40 $15.04 $15.08 225 300
Oct 07, 2016 $15.46 $15.67 $15.10 $15.23 53 800
Oct 06, 2016 $15.77 $15.79 $15.17 $15.36 65 700
Oct 05, 2016 $15.63 $16.25 $15.03 $15.89 82 100
Oct 04, 2016 $15.76 $15.98 $15.34 $15.49 103 800
Oct 03, 2016 $15.74 $16.18 $15.32 $15.52 120 300
Sep 30, 2016 $15.70 $16.03 $15.40 $15.68 90 900
Sep 29, 2016 $16.46 $16.46 $15.46 $15.53 58 000
Sep 28, 2016 $16.07 $16.75 $15.89 $16.32 97 500
Sep 27, 2016 $15.93 $16.59 $15.71 $15.95 87 100
Sep 26, 2016 $15.65 $15.99 $15.24 $15.86 110 500
Sep 23, 2016 $16.72 $17.06 $15.39 $15.64 190 500
Sep 22, 2016 $17.39 $17.39 $16.15 $16.66 190 400
Sep 21, 2016 $17.47 $17.79 $16.44 $17.38 114 100
Sep 20, 2016 $16.33 $17.50 $16.13 $17.19 135 500
Sep 19, 2016 $15.69 $16.20 $15.26 $16.13 162 700
Sep 16, 2016 $15.32 $16.36 $14.95 $15.48 725 700
Sep 15, 2016 $15.79 $15.79 $14.65 $15.11 112 200
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT